NEW YORK (GenomeWeb) – QED Therapeutics said today that it has partnered with Foundation Medicine to develop a companion diagnostic for its drug candidate infigratinib in patients with cholangiocarcinoma (bile duct cancer).
Infigratinib is an FGFR1-3-selective tyrosine kinase inhibitor, and the CDx will include the detection of activating FGFR2 fusions. It is expected to be incorporated into FoundationOne CDx, Foundation Medicine's FDA-approved comprehensive genomic profiling assay for all solid tumors, which includes several companion diagnostics.
"Given infigratinib's demonstrated promise in FGFR2 fusion-driven cholangiocarcinoma, a companion diagnostic is critical to help physicians reliably identify which patients might be candidates for treatment," said Susan Moran, chief medical officer of QED Therapeutics, a subsidiary of BridgeBio Pharma, in a statement.
Foundation Medicine, which is part of Roche, has inked other CDx agreements this year, including with Novartis, Incyte, and Merck.